Cancer genetics, inc (CGIX)
CashFlow / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent

-10,180

-20,674

-20,534

-20,373

-24,509

-16,623

-15,756

-20,880

-15,755

-18,867

-20,129

-15,803

-18,741

-20,208

-21,160

-20,184

-19,643

-19,228

-18,435

-16,643

-13,994

-12,263

-17,219

-12,373

-13,892

-10,514

-3,232

-6,665

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1,524

1,554

1,443

1,602

483

895

1,694

1,799

1,966

1,997

2,048

2,032

2,034

1,839

1,673

1,503

1,293

1,275

1,061

810

571

374

330

311

299

315

332

338

0

0

0

Amortization

461

477

463

512

511

458

418

366

317

335

339

343

393

316

237

159

33

31

30

28

23

20

17

15

15

15

15

15

0

0

0

Provision for bad debts

-

-

2,050

-

-

-

5,763

5,278

1,605

959

702

723

208

197

192

413

428

431

436

215

0

0

0

-

-

-

-

-4

0

0

0

Stock-based compensation

744

639

805

921

903

1,561

1,734

1,895

1,873

1,868

1,917

2,016

2,194

2,404

2,672

2,834

0

0

0

-

-

-

-

-

-

-

0

-

0

0

0

Change in fair value of warrant liability, acquisition note payable and other derivatives

-1,187

-1,147

-3,097

-3,782

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity-based consulting and compensation expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of acquisition note payable

-

-

-

-

-

-

-

-

-

168

114

-152

-479

-776

-393

-269

-107

208

-108

-198

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

5,209

5,786

-1,525

-746

-248

-67

-35

-111

-26

-446

-417

-861

301

710

-4,633

0

0

0

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Amortization of discount of debt and debt issuance costs

930

987

1,577

517

1,171

1,268

1,292

1,299

188

37

15

12

12

12

12

8

5

2

0

311

621

892

1,097

1,195

1,359

1,492

1,590

1,427

0

0

0

Interest added to Convertible Note

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discount on debt

-

-

-

-

-

-

-

-

-

48

7

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

585

1,237

1,864

2,346

2,212

0

0

0

Income (Loss) from Equity Method Investments

-150

-151

-152

-154

-5

-6

-12

-22

-49

-65

-73

-73

-4

-329

-512

-707

-1,028

-1,034

-1,135

-940

0

0

0

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-78

-78

-78

-78

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Deferred initial public offering costs expensed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

618

0

0

0

-

-

-

-

Changes in:
Accounts receivable

-484

-1,169

-947

-1,041

-967

1,988

2,842

3,583

2,813

2,165

4,923

5,850

8,379

6,075

3,473

1,662

1,484

2,077

1,422

1,657

472

793

693

717

772

526

321

156

0

0

0

Other current assets

-195

-204

-199

-330

-27

-276

458

159

595

574

195

56

83

-221

112

384

397

301

111

199

321

509

450

375

261

234

56

220

0

0

0

Operating lease right-of-use assets

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

61

5

-6

-1

246

32

33

0

-191

19

44

69

24

40

98

101

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued expenses and deferred revenue

4,745

3,871

2,994

3,766

261

1,024

-1,123

-1,538

-1,074

-1,753

-238

355

2,156

2,699

3,252

3,114

1,019

1,067

567

675

1,509

-626

-1,760

-731

-1,025

-144

2,333

85

0

0

0

Obligations under operating leases

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent payable and other

8

19

18

42

77

92

115

152

118

99

80

25

-10

4

21

33

78

63

52

38

16

10

-1

-6

0

0

0

-

-

-

-

Net Cash Provided by (Used in) Operating Activities, Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash used in operating activities

-6,652

-9,311

-12,545

-12,552

-14,754

-14,276

-15,645

-13,564

-10,801

-12,638

-14,455

-17,851

-20,948

-18,841

-16,281

-13,599

-14,378

-13,885

-13,506

-12,338

0

0

0

-

-

-

-

-7,577

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets

703

666

460

649

109

888

1,327

1,284

1,337

571

349

490

913

1,070

1,244

1,008

869

1,245

1,312

1,374

1,128

599

389

257

201

177

166

162

0

0

0

Net cash provided by (used in) investing activities, continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Decrease in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,000

0

0

0

-

-

-

-

50

0

0

0

Patent costs

-

-

-1

-

-

-

127

126

65

96

111

119

155

155

136

137

143

135

133

130

134

122

120

92

3

17

100

135

0

0

0

Net cash provided by investing activities

2,817

70

1,305

1,084

140

-1,079

-2,745

-2,701

-2,258

-867

-460

-609

-7,683

-8,720

-2,875

-2,640

4,107

749

-5,315

-11,373

0

0

0

-

-

-

-

-347

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on obligations under finance leases

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on obligations under finance leases

-

-

-

337

99

156

282

230

195

143

119

126

140

138

110

83

66

60

50

44

25

21

20

17

16

23

29

36

0

0

0

Payment of equity issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from warrant and option exercises

-

-

-

-

-

-

-

1,834

1,834

1,771

1,750

0

0

0

0

-

-

-

-

178

0

0

0

-

-

-

-

-

-

-

-

Proceeds from offerings of common stock, net of certain offering costs

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from option exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

79

0

0

0

-

-

-

-

-

-

-

-

Proceeds from offerings of common stock with derivative warrants, net of certain offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from borrowings on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,120

0

0

0

Proceeds from borrowings on Silicon Valley Bank line of credit

-

-

16,970

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of borrowings on Silicon Valley Bank line of credit

-

-

18,066

-

-

-

627

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities, continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from Partners for Growth IV, L.P. term note

-

-

-

-

-

-

-

-

-

-

6,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

-

-

-

-

-

-

-

287

287

287

287

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on Silicon Valley Bank term note

-

-

-

-

-

-

-

4,667

5,167

5,667

6,000

1,333

0

0

0

-

-

-

-

408

148

3,564

3,583

3,580

0

0

0

-

-

-

-

Net cash provided by financing activities

4,990

8,468

7,971

2,147

11,019

10,759

12,863

16,338

7,150

9,123

11,306

8,503

19,429

14,369

10,117

10,144

-560

-538

-182

-195

0

0

0

-

-

-

-

6,328

0

0

0

Effect of foreign exchange rates on cash and cash equivalents and restricted cash

-214

-161

-105

-59

44

77

-16

16

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents and restricted cash

941

-934

-3,374

-9,380

-3,551

-4,519

-5,543

89

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-9,957

-9,202

-13,192

-9,039

-6,095

-10,830

-13,674

-19,003

-23,906

20,870

35,477

41,098

48,640

8,974

1,539

-1,816

-1,597

0

0

0

SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest

1,629

1,327

1,330

1,271

1,065

1,099

847

871

716

541

505

333

332

370

303

240

193

138

131

128

130

179

510

608

900

1,095

977

1,091

0

0

0

SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangement

-

-

-

150

150

0

321

567

778

778

607

211

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative warrants issued with debt

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

125

0

0

0

-

-

-

-

-

-

-

-

Warrants issued for financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47

0

0

0

-

-

-

-

Retirement of treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

0

0

0

-

-

-

-

Offering costs discounted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

733

0

0

0

-

-

-

-

Conversion of notes payable, lines of credit and accrued interest to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Accrued IPO costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Warrants issued with debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Warrants issued for debt guarantee fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Payment of accrued IPO costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued expenses recorded as financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

251

0

0

0

Accrued expenses reclassified as derivative warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

221

0

0

0

-

-

-

-